Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 15/20 | 0.63 |
| ▸ | PNP | P00491 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993930 | 0.83 | HPRT1 (0.63) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL20782416 | 0.80 | HPRT1 (0.65) | HPRT1PNP | |
| SCHEMBL11258920 | 0.80 | HPRT1 (0.69) | HPRT1PNP | |
| SCHEMBL27670854 | 0.80 | HPRT1 (0.56) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL22381490 | 0.79 | HPRT1 (0.63) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL455645 | 0.79 | HPRT1 (0.62) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL7569894 | 0.79 | HPRT1 (0.58) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL3060815 | 0.79 | HPRT1 (0.63) | HPRT1PNP | |
| SCHEMBL18521979 | 0.77 | PNP (0.66) | HPRT1PNPMEN1LMNAKMT2A | |
| SCHEMBL13145301 | 0.77 | HPRT1 (0.51) | HPRT1PNPMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | HPRT1 226/4885PNP 384/4885MEN1 1605/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | HPRT1 274/4885PNP 462/4885MEN1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.